Kolon Ramps Up For Novel Osteoarthritis Cell Therapy
This article was originally published in PharmAsia News
Executive Summary
South Korea's Kolon Life Science is gearing up for mass production of Invossa, the world's first cell-mediated gene therapy for osteoarthritis, as it prepares to file for a domestic approval and a US Phase III study. The venture also plans to raise around $114m to hike its biologics production capacity.
You may also be interested in...
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
New Funding To Give ViroMed ‘Favorable Position’ For Gene Therapy Deal
ViroMed joins a group of South Korean bioventures launching share offerings to fund R&D activities, in its case to beef up the clinical data package for its lead project VM202, which should in turn help with a licensing out deal for the gene therapy.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.